Developing Therapies to Save Lives

Rainier Therapeutics, Inc. is a privately-held, clinical stage biotechnology company developing a targeted biologic for the potential treatment of both early stage and metastatic bladder cancer, areas of high unmet need.

Vofatamab
(B-701)

Our lead program is a human monoclonal antibody, known as vofatamab, that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist known in development.